Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy.
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
12
01
2023
revised:
03
02
2023
accepted:
03
02
2023
entrez:
2
3
2023
pubmed:
3
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
The absence of T cells in the tumor microenvironment of solid tumors is a major barrier to cancer immunotherapy efficacy. Oncolytic viruses, including reovirus type 3 Dearing (Reo), can recruit CD8 Blockade of the pleiotropic molecule TGF-β can both improve and impair the efficacy of viro-immunotherapy, depending on the tumor model. While TGF-β blockade antagonized Reo&CD3-bsAb combination therapy in the KPC3 model for pancreatic cancer, it resulted in 100% complete responses in the MC38 colon model. Understanding factors underlying this contrast is required to guide therapeutic application.
Identifiants
pubmed: 36860656
doi: 10.1158/2767-9764.CRC-23-0019
pii: CRC-23-0019
pmc: PMC9973387
doi:
Substances chimiques
Transforming Growth Factor beta
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
325-337Informations de copyright
© 2023 The Authors; Published by the American Association for Cancer Research.
Références
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
Cells. 2019 Apr 05;8(4):
pubmed: 30959852
MAbs. 2016;8(2):389-404
pubmed: 26563652
Cancer Cell. 2005 May;7(5):469-83
pubmed: 15894267
J Immunother Cancer. 2019 Mar 4;7(1):62
pubmed: 30832732
Blood. 2002 Jul 15;100(2):560-8
pubmed: 12091349
PLoS One. 2018 Sep 27;13(9):e0204622
pubmed: 30261045
Mol Ther. 2014 May;22(5):1056-62
pubmed: 24553100
J Thorac Oncol. 2011 Jan;6(1):209-17
pubmed: 21107292
Sci Transl Med. 2018 Jan 3;10(422):
pubmed: 29298869
J Immunol. 2015 May 1;194(9):4397-412
pubmed: 25825443
Gastroenterology. 2010 Mar;138(3):969-80.e1-3
pubmed: 19909744
Cancers (Basel). 2021 Oct 11;13(20):
pubmed: 34680235
BMC Gastroenterol. 2015 Sep 02;15:109
pubmed: 26330349
Nat Rev Immunol. 2022 Nov 15;:
pubmed: 36380023
PLoS One. 2011;6(11):e27090
pubmed: 22096521
Oncolytic Virother. 2018 Jun 14;7:53-63
pubmed: 29942799
Cancer Res. 2015 Jun 1;75(11):2232-42
pubmed: 25858148
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33082167
Cancer Res. 2013 Mar 15;73(6):1721-32
pubmed: 23345161
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142841
Int J Biol Sci. 2012;8(7):964-78
pubmed: 22811618
Control Clin Trials. 1990 Apr;11(2):116-28
pubmed: 2161310
Cancer Discov. 2021 Mar;11(3):736-753
pubmed: 33158848
J Virol. 2009 May;83(10):5035-45
pubmed: 19279118
Sci Rep. 2018 Feb 13;8(1):2918
pubmed: 29440769
Nature. 2018 Feb 22;554(7693):538-543
pubmed: 29443964
J Clin Microbiol. 2013 Sep;51(9):3047-54
pubmed: 23850952
Cell Biosci. 2017 Aug 7;7:39
pubmed: 28794854
J Exp Clin Cancer Res. 2019 Mar 6;38(1):115
pubmed: 30841909
Cancer Res. 2004 Aug 1;64(15):5200-11
pubmed: 15289325
Cancers (Basel). 2018 May 25;10(6):
pubmed: 29799479
J Immunother Cancer. 2019 Sep 3;7(1):236
pubmed: 31481117
Curr Protoc Pharmacol. 2016 Jun 01;73:14.39.1-14.39.20
pubmed: 27248578
J Clin Invest. 2022 Apr 15;132(8):
pubmed: 35230974
Cancers (Basel). 2021 Mar 19;13(6):
pubmed: 33808627
Mol Cancer Ther. 2019 Feb;18(2):312-322
pubmed: 30381448
J Pharmacol Sci. 2014;124(2):230-43
pubmed: 24492413
Cell. 2008 Jul 25;134(2):215-30
pubmed: 18662538
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16618-23
pubmed: 22996328
Nat Commun. 2020 Dec 9;11(1):6315
pubmed: 33298926
Clin Cancer Res. 2021 Nov 15;27(22):6156-6163
pubmed: 34465600
Oncoimmunology. 2017 Mar 31;6(5):e1308616
pubmed: 28638730
Immunity. 2019 Apr 16;50(4):924-940
pubmed: 30995507
Front Oncol. 2020 Jul 08;10:979
pubmed: 32733792
PLoS One. 2012;7(10):e48064
pubmed: 23110175
EMBO Mol Med. 2019 Nov 7;11(11):e10515
pubmed: 31609088
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Immunity. 2018 Apr 17;48(4):626-628
pubmed: 29669246
Cancers (Basel). 2021 Jan 22;13(3):
pubmed: 33499083
Cell. 2019 Nov 14;179(5):1177-1190.e13
pubmed: 31730856
J Immunother Cancer. 2018 Jun 4;6(1):47
pubmed: 29866156
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33046622
Br J Cancer. 2014 Nov 11;111(10):1917-23
pubmed: 25314063
Clin Cancer Res. 2014 Dec 1;20(23):5946-55
pubmed: 25294913
Front Cell Dev Biol. 2018 Feb 28;6:17
pubmed: 29541636
Mol Cancer Ther. 2016 May;15(5):767-73
pubmed: 27197256
Trends Immunol. 2020 May;41(5):406-420
pubmed: 32223932
J Cell Biochem. 2019 Jun;120(6):8899-8907
pubmed: 30556274
Cell Microbiol. 2016 Dec;18(12):1831-1845
pubmed: 27279006
Clin Cancer Res. 2020 Feb 1;26(3):643-656
pubmed: 31582516